Coeptis Therapeutics Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has disclosed a beneficial ownership of 3.41% in Z Squared Inc., holding over 1.75 million shares.
NASDAQ
Vanguard Capital Management and its affiliates have reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Coeptis Therapeutics Holdings Inc. due to an internal realignment.
NASDAQ
The Vanguard Group and its affiliates reported a 6.35% beneficial ownership stake in Coeptis Therapeutics Holdings Inc. as of December 31, 2025.